Skip to main content
HCPCS J9359 · Level II · Part B drug

J9359: loncastuximab tesirine-lpyl (Zynlonta), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9359

Billing unit
0.075 MG
Inj lon tesirin-lpyl 0.075mg
ASP payment limit
$226.565
October 2026; -0.0% vs July 2026
Practitioner MUE
400
MAI 3
OPPS status
SI K
APC 9205
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9359 is the Level II code for Injection, loncastuximab tesirine-lpyl, 0.075 mg, billed per 0.075 MG. The Medicare Part B ASP payment limit for October 2026 is $226.565 per billing unit, down 0.0% from July 2026. The practitioner MUE allows up to 400 units per date of service (MAI 3), so a full 400-unit day is $90,626.00 at the current limit. Under OPPS it carries status indicator K in APC 9205. J9359 is billed in units of 0.075 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Zynlonta by ADC Therapeutics America, Inc. No current Billing and Coding Article lists J9359, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9359 at $226.565 per 0.075 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $226.608 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9359
QuarterPayment limitPerCoinsurance
October 2026$226.5650.075 MG20%
July 2026$226.6080.075 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J9359. Report the NDC in the claim's drug segment and bill the number of J9359 units that equals the quantity administered divided by 0.075 MG; the last column gives units per full package.

NDCs that crosswalk to J9359
NDCDrug nameLabelerPackage sizeBilling units / package
79952-0110-01ZynlontaADC Therapeutics America, Inc.1 × 1134

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J9359. For practitioners the limit is 400 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9359 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services4003 Date of Service Edit: ClinicalCMS Policy
Facility outpatient hospital4003 Date of Service Edit: ClinicalCMS Policy

MUE for J9359 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9359 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9359 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9359 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9359 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9359 carries status indicator K and is assigned to APC 9205, with a published national unadjusted payment of $226.565. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9359 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $226.57 per 0.075 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J9359 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9359

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9359

What does HCPCS code J9359 describe?

J9359 is defined by CMS as "Injection, loncastuximab tesirine-lpyl, 0.075 mg". Each billing unit represents 0.075 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9359 a CPT code?

No. J9359 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as loncastuximab tesirine-lpyl (Zynlonta); CPT codes are five-character codes maintained by the AMA. On a Part B claim J9359 reports the drug itself in 0.075 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9359 in October 2026?

The ASP-based payment limit is $226.565 per 0.075 MG, with 20% beneficiary coinsurance. The July 2026 limit was $226.608. Commercial payers use their own fee schedules.

How many units of J9359 can be billed per day?

The practitioner Medically Unlikely Edit is 400 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "CMS Policy" as the rationale.

Which NDCs map to J9359?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Zynlonta (ADC Therapeutics America, Inc.). For example NDC 79952-0110-01 (package size 1) equals 134 billing units of J9359.

Does J9359 have NCCI bundling edits?

No active practitioner PTP pairs list J9359 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.